thereof.

51. A method of providing controlled delivery of α -lipoic acid or a derivative thereof in a subject comprising administering to said subject the sustained release form of claim 27 wherein said sustained release form provides controlled release of an active ingredient for a period of more than about 8 hours.

52. A method for increasing the bioavailability of α -lipoic acid or/and derivatives thereof comprising preparing the sustained release form of claim 27 and administering the sustained release form to a patient.

REMARKS

Early and favorable action on the merits is earnestly solicited.

It is not believed that any fees are due for entering this amendment. If it is determined that any fees are due, the Commissioner is authorized to charge such fees to Deposit Account No. 50-0624.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

James R. Crawford

Reg/No. 39,155

666 Fifth Avenue New York, N.Y. 10103 (212) 318-3148 thereof.

51. A method of providing controlled delivery of α -lipoic acid or a derivative thereof in a subject comprising administering to said subject the sustained release form of claim 27 wherein said sustained release form provides controlled release of an active ingredient for a period of more than about 8 hours.

52. A method for increasing the bioavailability of α -lipoic acid or/and derivatives thereof comprising preparing the sustained release form of claim 27 and administering the sustained release form to a patient.

REMARKS

Early and favorable action on the merits is earnestly solicited.

It is not believed that any fees are due for entering this amendment. If it is determined that any fees are due, the Commissioner is authorized to charge such fees to Deposit Account No. 50-0624.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

James R. Crawford Reg. No. 39,155

666 Fifth Avenue New York, N.Y. 10103 (212) 318-3148

6